Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of LN-145 tumor-infiltrating lymphocytes in metastatic non-small-cell lung cancer
NL-OMON59436Phase 2Active, not recruiting
- Sponsor
- Iovance Biotherapeutics
- Start
- Dec 2021
- Modality
- Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of LN-145 in non-small cell lung cancer (NSCLC) (5 cohorts), sponsored by Iovance Biotherapeutics. Primary endpoint: Objective response rate. Started Dec 2021; status: active, not recruiting.
02
Drugs
LN-145
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59436.